Loading
Tests whether the anthracycline can be dropped from TNBC pre-surgery treatment without losing effect.
SCARLET, SWOG trial S2212, NCT05929768, sponsored by SWOG and the NCI, tests whether the anthracycline can be dropped from pre-surgery treatment of stage II to III triple-negative breast cancer without losing effect, comparing an anthracycline-free regimen of carboplatin, docetaxel and pembrolizumab with the KEYNOTE-522 regimen. It is a non-inferiority trial of 2,400 patients with event-free survival as the primary endpoint, and success would reduce cardiotoxicity and leukaemia risk; it is ongoing with no results. OnCo links it to triple-negative breast cancer, pembrolizumab, carboplatin, the TNBC roadmap, the idea of neoadjuvant ADC plus immunotherapy replacing anthracyclines, the SWOG Cancer Research Network and Priyanka Sharma. Whether de-escalation informed by tumour-infiltrating lymphocytes and pembrolizumab can safely retire anthracyclines is the question it will answer.
Shares Give exceptional responders less: pembrolizumab omission after complete response, anthracycline-free regimens and chemotherapy omission in lymphocyte-rich stage I disease, TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, KEYNOTE-522, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem.
Shares Neoadjuvant ADC + IO replacing anthracycline chemotherapy in TNBC, Give exceptional responders less: pembrolizumab omission after complete response, anthracycline-free regimens and chemotherapy omission in lymphocyte-rich stage I disease, KEYNOTE-522, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem.
Shares SWOG Cancer Research Network, KEYNOTE-522, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites).
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Carboplatin, Pembrolizumab.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Carboplatin, Pembrolizumab.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Carboplatin, Pembrolizumab.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Carboplatin, Pembrolizumab.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Carboplatin, Pembrolizumab.